We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Hematology Malignancy Physician Publications

Stem Cell Transplantation

Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik L.. J Clin Oncol. 2014 Nov 1;32(31):3497-505.

Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. Hourigan CS, McCarthy P, de Lima M Biol Blood Marrow Transplant. 2014 Feb;20(2):154-63. doi: 10.1016/j.bbmt.2013.11.017. Epub 2013 Nov 27. PMID: 24291784

Cord Blood Transplantation: Can We Make it Better? Metheny L, Caimi P, de Lima M Front Oncol. 2013 Sep 17;3:238. PMID:24062989

Cord-blood engraftment with ex vivo mesenchymal-cell coculture. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. N Engl J Med. 2012 Dec 13;367(24):2305-15. doi: 10.1056/NEJMoa1207285. PMID: 23234514

Hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. Deeg HJ, de Lima M. J Natl Compr Canc Netw. 2013 Oct 1;11(10):1227-33. PMID: 24142824

Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit. Bayraktar UD, Shpall EJ, Liu P, Ciurea SO, Rondon G, de Lima M, Cardenas-Turanzas M, Price KJ, Champlin RE, Nates JL. J Clin Oncol. 2013 Nov 20;31(33):4207-14. doi: 0.1200/JCO.2013.50.5867. Epub 2013 Oct 14.PMID: 24127454

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation. de Lima M, Porter DL, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Schmid C. Biol Blood Marrow Transplant. 2014 Jan;20(1):4-13. doi: 10.1016/j.bbmt.2013.08.012. Epub 2013 Sep 7.PMID:24018392

Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. Fernández-Viña MA, Klein JP, Haagenson M, Spellman SR, Anasetti C, Noreen H, Baxter-Lowe LA, Cano P, Flomenberg N, Confer DL, Horowitz MM, Oudshoorn M, Petersdorf EW, Setterholm M, Champlin R, Lee SJ, de Lima M. Blood. 2013 May 30;121(22):4603-10. doi: 10.1182/blood-2013-02-481945. Epub 2013 Apr 17.PMID:23596045

Phase I/II Study of VELCADE®-BEAM (V-BEAM) and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Indolent Non-Hodgkin lymphoma (NHL), Transformed, or Mantle Cell Lymphoma (MCL). William BM, Allen MS, Loberiza FR Jr, Bociek RG, Bierman PJ, Armitage JO, Vose JM. Biol Blood Marrow Transplant. 2014 Jan 13. pii: S1083-8791(14)00020-2. doi: 10.1016/j.bbmt.2014.01.004. [Epub ahead of print]

Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma. William BM, Loberiza FR Jr, Whalen V, Bierman PJ, Bociek RG, Vose JM, Armitage JO. Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):417-23. doi: 10.1016/j.clml.2013.03.009. Epub 2013 Jun 15.

Epigenetic therapy in allogeneic hematopoietic stem cell transplantation. Bashir Q, William BM, Garcia-Manero G, de Lima M. Rev Bras Hematol Hemoter. 2013;35(2):126-33. doi: 10.5581/1516-8484.20130034.

Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies. William BM, de Lima M. Drugs Aging. 2013 Jun;30(6):373-81. doi: 10.1007/s40266-013-0076-x.

Charlson Comorbidity Index (CCI) and Hematopoietic Cell Transplantation Specific-Comorbidity Index (HCT-CI) Do Not Predict Transplant Related Mortality (TRM) and Post-Transplant Outcomes In Young Patients Undergoing Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation. Paun OV, Kindwall-Keller TL, Lazarus HL, Laughlin MJ, Caimi PF, Kolk MJ, Creger RJ, Salman H, Gerson SL, Cooper BW Blood 122:4582, 2013.

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M, Akpek G, Aljurf M, Cahn JY, Cairo M, Chen YB, Cooper B, Deol A, Giralt S, Gupta V, Khoury HJ, Kohrt H, Lazarus HM, Lewis I, Olsson R, Pidala J, Savani BN, Seftel M, Socié G, Tallman M, Ustun C, Vij R, Vindeløv L, Weisdorf D. Blood. 2012;119(17):4083-90. PMID: 22408257

Prospective study of one vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies. Kindwall-Keller TL, Hagerfeldt Y, Meyerson HJ, Margevicius S, Fu P, van Heeckeren W, Lazarus HM, Cooper BW, Gerson SL, Barr P, Tse WW, Curtis C, Fanning LR, Creger RJ, Carlson-Bark JM, Laughlin MJ. Bone Marrow Transplantation, 47: 924-33, 2012.

In adults with standard-risk acute lymphoblastic leukemia (ALL) the greatest benefit is achieved from a matched sibling allogeneic transplant in first complete remission (CR) and an autologous transplant is less effective than conventional consolidation/maintenance chemotherapy in all patients. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, Paietta E, Litzow MR, Marks D, Durrant J, McMillan A, Franklin I, Luger S, Ciobanu N, Rowe JM. Blood 111: 1827-1833, 2008.

Rapid transport and infusion of hematopoietic cells is associated with improved outcome after myeloablative therapy and unrelated donor transplant. Lazarus HM, Kan F, Tarima S, Champlin RE, Confer DL, Frey N, Gee AP, Wagner JE, Horowitz MM, Eapen M. Biol Blood Marrow Transplant 15: 589-596, 2009.

Superior survival after autologous versus myeloablative HLA-identical sibling transplant for diffuse large B-cell lymphoma: A report from the CIBMTR. Lazarus HM, Zhang M-J, Carreras J, Hayes-Lattin BM, Ataergin SA, Bitran JD, Bolwell BJ, Freytes CO, Gale RP, Goldstein SC, Hale GA, Inwards DJ, Klumpp TR, Marks DI, Maziarz RT, McCarthy PL, Pavlovsky S, Rizzo JD, Shea TC, Schouten HC, Slavin S, Winter JN, van Besien K, Vose JM, Hari PN. Biol Blood Marrow Transplant 16: 35-45, 2010.

Emerging therapeutic approaches for multipotent mesenchymal stromal cells. Caimi PF, Reese J, Lee Z, Lazarus HM. Curr Opin Hematol. 2010 Nov;17(6):505-13. doi:10.1097/MOH.0b013e32833e5b18. Review. PubMed PMID: 20729733; PubMed Central PMCID: PMC3748957.

Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M. J Clin Oncol. 2016 Sep 10;34(26):3141-9. PMID:27269951

Aging and transplanting graciously. de Lima M. Lancet Haematol. 2015 Oct;2(10):e398-9. doi: 10.1016/S2352-3026(15)00193-3. Epub 2015 Sep 18. PMID:26686036

New approaches to transplantation in acute myelogenous leukemia. de Lima M. Hematology Am Soc Hematol Educ Program. 2015;2015:596-604. PMID:26637777

Reduced Intensity Conditioned Allograft Yields Favorable Survival for Older Adults with B-cell Acute Lymphoblastic Leukemia. Rosko A, Wang HL, de Lima M, Sandmaier B, Khoury HJ, Artz A, Brammer J, Bredeson C, Farag S, Kharfan-Dabaja M, Lazarus HM, Marks DI, Martino Bufarull R, McGuirk J, Mohty M, Nishihori T, Nivison-Smith I, Rashidi A, Ringden O, Seftel M, Weisdorf D, Bachanova V, Saber W. Am J Hematol. 2016 Oct 6. doi: 10.1002/ajh.24575. PMID: 27712033

Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant. Ueda M, de Lima M, Caimi P, Tomlinson B, Little J, Creger R, Lazarus H, Cooper B. Bone Marrow Transplant. 2016 Sep;51(9):1253-5. doi: 10.1038/bmt.2016.104. Epub 2016 Apr 18. PMID: 27088374

Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients. Caimi PF, William BM, Silva Rondon CH, Fu P, Cooper BW, Campagnaro EL, Gerson SL, Reese-Koc J, Fox R, Creger RJ, de Lima M, Lazarus HM. Biol Blood Marrow Transplant. 2015 Nov;21(11):1926-31. PMID:26087475

Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment. Afable M, Caimi PF, Hosing C, de Lima M, Khouri I, William BM, Nieto Y, Cooper BW, Anderlini P, Gerson SL, Lazarus HM, Champlin R, Popat U. Biol Blood Marrow Transplant. 2015 Aug;21(8):1529-31. doi: 10.1016/j.bbmt.2015.04.022. PMID:25937397

Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation. Auletta JJ, Eid SK, Wuttisarnwattana P, Silva I, Metheny L, Keller MD, Guardia-Wolff R, Liu C, Wang F, Bowen T, Lee Z, Solchaga LA, Ganguly S, Tyler M, Wilson DL, Cooke KR. Stem cells (Dayton, Ohio). 2015; 33(2):601-14. NIHMSID: NIHMS635903. PMID: 25336340. PMCID: PMC4304927.

Intra-osseous Co-transplantation of CD34-selected Umbilical Cord Blood and Mesenchymal Stromal Cells. Metheny L 3rd, Eid S, Lingas K, Reese J, Meyerson H, Tong A, de Lima M, Huang AY. Hematology & medical oncology. 2016; 1(1):25-29. NIHMSID: NIHMS828364. PMID: 27882356. PMCID: PMC5117423.

Going home for the holidays? Take a shortcut! Metheny L, de Lima M. Bone marrow transplantation. 2017; 52(4):514-515. PMID: 28112751.

Umbilical Cord Blood Banking and Transplantation. Caimi P, Metheny L, Marcos D. Ballen K, editor. New York: Springer; 2014. Cord Blood ex vivo expansion


Clinical cancer advances 2013: annual report on progress against cancer from the american society of clinical oncology. Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, Carroll WL, de Lima M, Gilbert MR, Kris MG, Marshall JL, Masters GA, O'Day SJ, Polite B, Schwartz GK, Sharma S, Thompson I, Vogelzang NJ, Roth BJ. J Clin Oncol. 2014 Jan 10;32(2):129-60. doi: 10.1200/JCO.2013.53.7076. Epub 2013 Dec 10.PMID:24327669

Phase I study of Midostaurin and Azacitidine in Relapsed and Elderly AML, Cooper BW, Kindwall-Keller TL, Lazarus HM, Hamadani M, Tse WW, Basu SK, Craig M J Clin Oncol 31: supp; abstr 7058, 2013

Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemia. Van Heeckeren WJ, Fu PF, Barr PM, Arfonse LM, Kirschbaum MH, Lazarus HM, Cooper BW. Journal of Geriatric Oncology 2: 215-221,2011

Anthracycline dose intensification in acute myeloid leukemia. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. N Engl J Med 361:1249-1259, 2009.

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL. N Engl J Med 366: 1079-89, 2012.

Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Harr MW, Caimi PF, McColl KS, Zhong F, Patel SN, Barr PM, Distelhorst CW. Cell Death Differ. 2010 Sep;17(9):1381-91. doi: 10.1038/cdd.2010.25. Epub 2010 Mar 19. PubMed PMID: 20300113; PubMed Central PMCID: PMC3130993.

Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL). Hill BT, Caimi P, Kindwall-Keller T, Habecker B, Kalaycio M. Br J Haematol. 2014 Jan;164(2):297-9. doi: 10.1111/bjh.12604. Epub 2013 Oct 17. PubMed PMID: 24131326.

A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity. Hu S, Ueda M, Stetson L, Ignatz-Hoover J, Moreton S, Chakrabarti A, Xia Z, Karan G, de Lima M, Agrawal MK, Wald DN. Mol Cancer Ther. 2016 Jul;15(7):1485-94. PMID:27196775

NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO, Ontiveros E, Purev E, Quiery A, Reddy VV, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Tibes R, Yang DT, Gregory K, Sundar H, Deininger M, Radich JP. Journal of the National Comprehensive Cancer Network: JNCCN. 2016; 14(12):1505-1512. PMID: 27956535.


The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma. William BM, Bongu NR, Bast M, Bociek RG, Bierman PJ, Vose JM, Armitage JO. Rev Bras Hematol Hemoter. 2013;35(3):189-91. doi: 10.5581/1516-8484.20130055.

International analysis of the frequency and outcomes of NK/T-cell lymphomas. William BM, Armitage JO. Best Pract Res Clin Haematol. 2013 Mar;26(1):23-32. doi: 10.1016/j.beha.2013.04.003. Epub 2013 May 24.

Non-Hodgkin's lymphoma in the elderly. Caimi PF, Barr PM, Berger NA, Lazarus HM. Drugs Aging. 2010 Mar 1;27(3):211-38. doi: 10.2165/11531550-000000000-00000. PubMed PMID: 20210368.

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI. Ann Oncol. 2013 Dec;24(12):3076-81. doi: 10.1093/annonc/mdt414. Epub 2013 Oct 20. PubMed PMID: 24146219; PubMed Central PMCID: PMC3841019.

Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era. Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Br J Haematol. 2016 Jul 22. PMID: 27443247

Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes. Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Singh AD, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Br J Haematol. 2016 May;173(3):404-12. doi: 10.1111/bjh.13975. PMID:26953041

Multiple Myeloma

Symptom burden after autologous stem cell transplant for multiple myeloma. Campagnaro E, Saliba R, Giralt S, Roden L, Mendoza F, Aleman A, Cleeland C, Weber D, Brown J, Anderson KO. Cancer 2008; 112(7): 1617-1623. http://www.ncbi.nlm.nih.gov/pubmed/18260091

Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. Jakubowiak AJ, Kendall T, Al-zoubi A, Khaled Y, Mineishi S, Ahmed A, Campagnaro E, Brozo C, Braun T, Talpaz M, Kaminski MS. J Clin Oncol. 2009; 27(30):5015-22. http://www.ncbi.nlm.nih.gov/pubmed/19738129

A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. Saiya-Cork K, Collins R, Parkin B, Ouillette P, Kuizon E, Kujawski L, Erna H, Campagnaro E, Shedden K, Kaminski M, Malek SN. Clin Cancer Res. 2011 May 1;17(9):2679-92. http://www.ncbi.nlm.nih.gov/pubmed/21307146

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Jakubowiak AJ, Griffith KA, Reece DE, Hofmeister CC, Lonial S, Zimmerman TM, Campagnaro EL, Schlossman RL, Laubach JP, Raje NS, Anderson T, Mietzel M, Harvey C, Wear SM, Barrickman JC, Tendler CL, Esseltine D-L, Kelley SL, Kaminski MS, Anderson KC, and Richardson PG. Blood. 2011 Jul 21;118(3):535-43. http://www.ncbi.nlm.nih.gov/pubmed/21596852

Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: a matter of undetermined significance. Manson GV, Campagnaro E, Balog A, Kaplan D, Sommers SR, Fu P, Rajkumar SV, Lazarus HM. Bone Marrow Transplant. 2012 Sep;47(9):1212-6 http://www.ncbi.nlm.nih.gov/pubmed/22158387

Resistant or Sensitive: Time is of the Essence. Malek E, de Lima M, Caimi P. Biol Blood Marrow Transplant. 2016 Oct;22(10):1907-8. PMID: 27392464

Myeloid-derived suppressor cells: The green light for myeloma immune escape. Malek E, de Lima M, Letterio JJ, Kim BG, Finke JH, Driscoll JJ, Giralt SA. Blood Rev. 2016 Sep;30(5):341-8. doi: 10.1016/j.blre.2016.04.002. Review. PMID: 27132116

Multiple myeloma presenting as mandibular ill-defined radiolucent lesion with numb chin syndrome: a case report. Elias HG, Scott J, Metheny L, Quereshy FA. Journal of oral and maxillofacial surgery: official journal of the American Association of Oral and Maxillofacial Surgeons. 2009; 67(9):1991-6.

Sickle Cell Disease

Traffic Light: prognosis-based eligibility for clinical trials of hematopoietic SCT in adults with sickle cell anemia. Rotz SJ, O'Riordan MA, Kim C, de Lima M, Gladwin MT, Little JA. Bone Marrow Transplant. 2015 Mar 16. doi: 10.1038/bmt.2015.11.

Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. Saraf SL, Zhang X, Kanias T, Lash JP, Molokie RE, Oza B, Lai C, Rowe JH, Gowhari M, Hassan J, Desimone J, Machado RF, Gladwin MT, Little JA, Gordeuk VR. Br J Haematol. 2013 Dec 12. doi: 10.1111/bjh.12690.

Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, Gibbs JS, Little JA, Schraufnagel DE, Krishnamurti L, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Onyekwere O, Castro OL, Sachdev V, Waclawiw MA, Woolson R, Goldsmith JC, Gladwin MT; walk-PHaSST Investigators and Patients. Blood. 2011 Jul 28;118(4):855-64. doi: 10.1182/blood-2010-09-306167. Epub 2011 Apr 28.

An elevated estimated pulmonary arterial systolic pressure, whenever measured, is associated with excess mortality in adults with sickle cell disease. Lorch D, Spevack D, Little J. Acta Haematol. 2011;125(4):225-9. doi: 10.1159/000323464. Epub 2011 Feb 1.

Induction of fetal/embryonic globin gene expression depends on intact cell signaling in definitive erythroid cells. Dutta A, Karkashon S, Raghupathy R, Bhatia H, Tesfa L, Little JA. Blood Cells Mol Dis. 2011 Feb 15;46(2):125-32. doi: 10.1016/j.bcmd.2010.10.013. Epub 2010 Nov 20.

Iron overload in sickle cell disease. Raghupathy R, Manwani D, Little JA. Adv Hematol. 2010;2010:272940. doi: 10.1155/2010/272940. Epub 2010 May 17.